NEW YORK ( TheStreet) -- Pain Therapeutics (Nasdaq: PTIE) hit a new 52-week high Thursday as it is currently trading at $10.38, above its previous 52-week high of $10.37 with 220,760 shares traded as of 11:02 a.m. ET. Average volume has been 425,100 shares over the past 30 days.

Pain has a market cap of $438 million and is part of the health care sector and drugs industry. Shares are up 48.1% year to date as of the close of trading on Wednesday.

Pain Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of novel drugs.
  • Practice your PTIE trading strategies and win cash in our stock game.

TheStreet Ratings rates Pain as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. You can view the full Pain Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

If you liked this article you might like

Ultragenyx Makes Bid for Dimension Therapeutics - Biotech Movers

5 Big-Volume Stocks You Should Stay Away From -- Plus 2 to Buy

For Pain Therapeutics CEO, 3 FDA Rejections Are Worth $23 Million

Pfizer (PFE) Stock Falls After Dropping Pain Drug

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan